RESUMEN
INTRODUCTION: Next-generation sequencing in cases of hereditary neuromuscular disorders often yields multiple candidate gene variants. Here, we describe a case with mutations in two genes, lamin A/C (LMNA) and exostosin glycosyltransferase 2 (EXT2), which led to hereditary myopathy combined with multiple exostoses. CASE HISTORY: A 51-year-old German woman with a history of removal of multiple exostoses during childhood presented with proximal limb-girdle muscular dystrophy and a newly diagnosed cardiomyopathy with atrioventricular conduction block. Because her younger son had exostoses and her younger brother had died at age 44 after heart transplantation due to dilated cardiomyopathy, an autosomal dominant inheritance was suspected. RESULTS: Muscle biopsy revealed features of chronic myopathy associated with focal myofibrillar disintegration. Electron microscopy showed myonuclear, myofibrillar, and Z-disc alterations, accumulations of granulofilamentous material, and a large sporadic osmiophilic inclusion body reminiscent of a nemaline body. Mendeliome and Sanger sequencing detected both a c.1129>T LMNA mutation of known pathogenicity and a c.1101_1102delAG (E368Kfs*18) truncating EXT2 mutation in the patient and her affected son. DISCUSSION: The clinical, genetic, and muscle biopsy findings suggest that both mutations are pathogenic. The EXT2 mutation was most likely responsible for the multiple exostoses phenotype in mother and son, whereas the myopathy was probably caused by a combined effect of the LMNA and EXT2 mutations.
Asunto(s)
Músculo Esquelético/patología , Distrofia Muscular de Cinturas/genética , Familia , Femenino , Humanos , Persona de Mediana Edad , Distrofia Muscular de Cinturas/patología , Mutación , Linaje , FenotipoRESUMEN
We present a case of a 26-year-old female patient with bloating, postprandial nausea and recurrent vomiting after solid food intake. A gastric emptying scintigraphy showed a delayed gastric emptying, defining gastroparesis. Because of her past medical history of short stature and pulmonary stenosis, we initiated genetic counseling where the diagnosis of Noonan syndrome was made. Dietary therapy and medication with domperidone quickly led to relief of the discomfort due to gastroparesis. However, prokinetics are not indicated for long-term therapy, as cardiac arrhythmia may occur. A risk-benefit assessment should be done. There are several novel approaches which need to be further investigated.
Asunto(s)
Dietoterapia , Domperidona/uso terapéutico , Gastroparesia/diagnóstico , Gastroparesia/terapia , Síndrome de Noonan/diagnóstico , Síndrome de Noonan/terapia , Adulto , Antieméticos/uso terapéutico , Terapia Combinada , Diagnóstico Diferencial , Femenino , Humanos , Resultado del TratamientoRESUMEN
Recent studies on the pathogenic mechanisms of recessive hyperekplexia indicate disturbances in glycine receptor (GlyR) α1 biogenesis. Here, we examine the properties of a range of novel glycine receptor mutants identified in human hyperekplexia patients using expression in transfected cell lines and primary neurons. All of the novel mutants localized in the large extracellular domain of the GlyR α1 have reduced cell surface expression with a high proportion of receptors being retained in the ER, although there is forward trafficking of glycosylated subpopulations into the ER-Golgi intermediate compartment and cis-Golgi compartment. CD spectroscopy revealed that the mutant receptors have proportions of secondary structural elements similar to wild-type receptors. Two mutants in loop B (G160R, T162M) were functional, but none of those in loop D/ß2-3 were. One nonfunctional truncated mutant (R316X) could be rescued by coexpression with the lacking C-terminal domain. We conclude that a proportion of GlyR α1 mutants can be transported to the plasma membrane but do not necessarily form functional ion channels. We suggest that loop D/ß2-3 is an important determinant for GlyR trafficking and functionality, whereas alterations to loop B alter agonist potencies, indicating that residues here are critical elements in ligand binding.
Asunto(s)
Retículo Endoplásmico/metabolismo , Aparato de Golgi/metabolismo , Espacio Intracelular/metabolismo , Neuronas/metabolismo , Receptores de Glicina/biosíntesis , Síndrome de la Persona Rígida/metabolismo , Secuencia de Aminoácidos , Animales , Células COS , Niño , Chlorocebus aethiops , Retículo Endoplásmico/genética , Femenino , Aparato de Golgi/genética , Células HEK293 , Humanos , Lactante , Masculino , Ratones , Datos de Secuencia Molecular , Linaje , Estructura Secundaria de Proteína , Estructura Terciaria de Proteína , Receptores de Glicina/química , Receptores de Glicina/genética , Síndrome de la Persona Rígida/diagnóstico , Síndrome de la Persona Rígida/genéticaAsunto(s)
Alopecia/diagnóstico , Alopecia/genética , Proteínas de la Membrana/genética , Proteínas Nucleares/genética , Osteopoiquilosis/diagnóstico , Osteopoiquilosis/genética , Enfermedades Cutáneas Genéticas/diagnóstico , Enfermedades Cutáneas Genéticas/genética , Alopecia/patología , Biopsia , Análisis Mutacional de ADN , Proteínas de Unión al ADN , Diagnóstico Diferencial , Femenino , Humanos , Persona de Mediana Edad , Osteopoiquilosis/patología , Cuero Cabelludo/patología , Enfermedades Cutáneas Genéticas/patologíaRESUMEN
Autosomal recessive congenital ichthyosis (ARCI) is a non-syndromic congenital disorder of cornification characterized by abnormal scaling of the skin. The three major phenotypes are lamellar ichthyosis, congenital ichthyosiform erythroderma, and harlequin ichthyosis. ARCI is caused by biallelic mutations in ABCA12, ALOX12B, ALOXE3, CERS3, CYP4F22, NIPAL4, PNPLA1, SDR9C7, SULT2B1, and TGM1. The most severe form of ARCI, harlequin ichthyosis, is caused by mutations in ABCA12. Mutations in this gene can also lead to congenital ichthyosiform erythroderma or lamellar ichthyosis. We present a large cohort of 64 patients affected with ARCI carrying biallelic mutations in ABCA12. Our study comprises 34 novel mutations in ABCA12, expanding the mutational spectrum of ABCA12-associated ARCI up to 217 mutations. Within these we found the possible mutational hotspots c.4541G>A, p.(Arg1514His) and c.4139A>G, p.(Asn1380Ser). A correlation of the phenotype with the effect of the genetic mutation on protein function is demonstrated. Loss-of-function mutations on both alleles generally result in harlequin ichthyosis, whereas biallelic missense mutations mainly lead to CIE or LI.
Asunto(s)
Eritrodermia Ictiosiforme Congénita , Ictiosis Lamelar , Humanos , Ictiosis Lamelar/genética , Genes Recesivos , Mutación , Eritrodermia Ictiosiforme Congénita/genética , Estudios de Asociación Genética , Transportadoras de Casetes de Unión a ATP/genética , Aciltransferasas/genética , Fosfolipasas/genéticaRESUMEN
We report on a young patient with a bicuspid aortic valve operated on for type A acute aortic dissection because of a blunt thoracic trauma. Aortic root replacement and ascending aortic and total arch repair together with the postoperative course were uneventful. Multigenerational genetic analyses revealed mutations in the NOTCH1 and ACTA2 genes in the patient and his father. The screening of his parents and children revealed no bicuspid aortic valve or aortic root dilation. This exceptionally rare case of double-hit mutations and the presence of blunt trauma reveals the complex etiology of aortic dissection in patients with a bicuspid aortic valve.
Asunto(s)
Disección Aórtica/complicaciones , Enfermedad de la Válvula Aórtica Bicúspide/complicaciones , Enfermedad de la Válvula Aórtica Bicúspide/genética , Mutación , Traumatismos Torácicos/complicaciones , Heridas no Penetrantes/complicaciones , Enfermedad Aguda , Adulto , Humanos , MasculinoRESUMEN
We report 2 cases of girls with MECP2 gene variants who do not have typical clinical features of Rett syndrome except for intellectual disability and seizures. Both patients present with adipositas, macrocephalia, precocious puberty, and seizures. They have prominent eyebrows and a short neck as well as short and plump fingers. Sequencing by NGS revealed a novel variant c.1162_1172del; p.Pro388* in both patients.
RESUMEN
Concomitant Loeys-Dietz syndrome (LDS) and hematologic malignancies are exceptionally rare. This is the first report of a patient operated on for aortic root dilation who had been previously diagnosed with LDS and B-cell-lymphoma. After completion of chemotherapy and complete remission, an elective valve-sparing aortic root replacement (using the David-V method) was performed. Due to the positive family history, pre-operative genetic counseling was conducted, and revealed LDS with a TGFBR1 (transforming growth factor beta receptor type I) mutation in 6 probands of the family, albeit in 1 of them posthumously. This missense mutation has been previously described in relation to aortic dissection, but a causative relationship to malignancy has so far neither been proposed nor proven.
RESUMEN
Variants in DONSON were recently identified as the cause of microcephaly, short stature, and limb abnormalities syndrome (MISSLA). The clinical spectra of MISSLA and Fanconi anaemia (FA) strongly overlap. For that reason, some MISSLA patients have been clinically diagnosed with FA. Here, we present the clinical data of siblings with MISSLA featuring a novel DONSON variant and summarize the current literature on MISSLA. Additionally, we perform computer-aided image analysis using the DeepGestalt technology to test how distinct the facial features of MISSLA and FA patients are. We show that MISSLA has a specific facial gestalt. Notably, we find that also FA patients feature facial characteristics recognizable by computer-aided image analysis. We conclude that computer-assisted image analysis improves diagnostic precision in both MISSLA and FA.
Asunto(s)
Proteínas de Ciclo Celular/genética , Enanismo/genética , Anemia de Fanconi/genética , Microcefalia/genética , Proteínas Nucleares/genética , Anomalías Múltiples/diagnóstico , Anomalías Múltiples/diagnóstico por imagen , Anomalías Múltiples/genética , Anomalías Múltiples/patología , Enanismo/diagnóstico , Enanismo/diagnóstico por imagen , Enanismo/patología , Anemia de Fanconi/diagnóstico , Anemia de Fanconi/diagnóstico por imagen , Anemia de Fanconi/patología , Femenino , Humanos , Lactante , Recién Nacido , Masculino , Microcefalia/diagnóstico , Microcefalia/diagnóstico por imagen , Microcefalia/patología , Mutación , Fenotipo , HermanosRESUMEN
OBJECTIVE: The study is aimed at widening the clinical and genetic spectrum and at assessing genotype-phenotype associations in QARS encephalopathy. METHODS: Through diagnostic gene panel screening in an epilepsy cohort, and recruiting through GeneMatcher and our international network, we collected 10 patients with biallelic QARS variants. In addition, we collected data on 12 patients described in the literature to further delineate the associated phenotype in a total cohort of 22 patients. Computer modeling was used to assess changes on protein folding. RESULTS: Biallelic pathogenic variants in QARS cause a triad of progressive microcephaly, moderate to severe developmental delay, and early-onset epilepsy. Microcephaly was present at birth in 65%, and in all patients at follow-up. Moderate (14%) or severe (73%) developmental delay was characteristic, with no achievement of sitting (85%), walking (86%), or talking (90%). Additional features included irritability (91%), hypertonia/spasticity (75%), hypotonia (83%), stereotypic movements (75%), and short stature (56%). Seventy-nine percent had pharmacoresistant epilepsy with mainly neonatal onset. Characteristic cranial MRI findings include early-onset progressive atrophy of cerebral cortex (89%) and cerebellum (61%), enlargement of ventricles (95%), and age-dependent delayed myelination (88%). A small subset of patients displayed a less severe phenotype. CONCLUSIONS: These data revealed first genotype-phenotype associations and may serve for improved interpretation of new QARS variants and well-founded genetic counseling.
RESUMEN
Recently, variants in DONSON have been reported to cause different disorders of the microcephalic primordial dwarfism spectrum. Using whole-exome sequencing, we identified two novel, compound heterozygous DONSON variants in a pair of siblings, one of whom was previously diagnosed with Fanconi anemia. This occurred because the present cases exhibited clinical findings in addition to those of the microcephalic primordial dwarfism disorder, including severe limb malformations. These findings suggest that the DONSON and Fanconi anemia proteins could have supplementary roles in developmental processes as they have in the maintenance of genomic integrity, resulting in related disease phenotypes.
Asunto(s)
Proteínas de Ciclo Celular/genética , Enanismo/genética , Deformidades Congénitas de las Extremidades/genética , Microcefalia/genética , Proteínas Nucleares/genética , Fenotipo , Feto Abortado/patología , Enanismo/patología , Femenino , Heterocigoto , Humanos , Lactante , Deformidades Congénitas de las Extremidades/patología , Microcefalia/patología , Mutación , SíndromeAsunto(s)
Síndrome del Corazón Izquierdo Hipoplásico/diagnóstico , Mutación/genética , Síndrome de Noonan/diagnóstico , Diagnóstico Prenatal , Proteínas Proto-Oncogénicas c-raf/genética , Adulto , Femenino , Pruebas Genéticas , Edad Gestacional , Humanos , Síndrome del Corazón Izquierdo Hipoplásico/complicaciones , Síndrome del Corazón Izquierdo Hipoplásico/genética , Síndrome de Noonan/complicaciones , Síndrome de Noonan/genética , Embarazo , Ultrasonografía PrenatalRESUMEN
We report on a patient operated on for degenerative myxomatous mitral and tricuspid valve disease (Barlow's disease) and aortic root dilatation. A valve repair operation and the postoperative course were uneventful. Multigenerational genetic analyses revealed two different mutations in the transforming growth factor beta-2 gene in the same patient. The two mutations in different exons were inherited from both parents each. None of the parents presented with either valve dysfunction or aortic root dilatation. This rare case illustrates potentially common genetic and signaling pathways of concomitant myxomatous valve disease and aortic root dilatation.
Asunto(s)
Aneurisma de la Aorta Torácica/genética , ADN/genética , Prolapso de la Válvula Mitral/genética , Mutación , Factor de Crecimiento Transformador beta2/genética , Aneurisma de la Aorta Torácica/diagnóstico , Aneurisma de la Aorta Torácica/cirugía , Procedimientos Quirúrgicos Cardíacos/métodos , Análisis Mutacional de ADN , Ecocardiografía Transesofágica , Femenino , Humanos , Persona de Mediana Edad , Prolapso de la Válvula Mitral/diagnóstico , Prolapso de la Válvula Mitral/cirugía , Tomografía Computarizada Multidetector , Factor de Crecimiento Transformador beta2/metabolismoRESUMEN
OBJECTIVES: Genetic defects associated with bicuspid aortopathy have been infrequently analysed. Our goal was to examine the prevalence of rare genetic variants in patients with a bicuspid aortic valve (BAV) with a root phenotype using next-generation sequencing technology. METHODS: We investigated a total of 124 patients with BAV with a root dilatation phenotype who underwent aortic valve ± proximal aortic surgery at a single institution (BAV database, n = 812) during a 20-year period (1995-2015). Cross-sectional follow-up revealed 63 (51%) patients who were still alive and willing to participate. Systematic follow-up visits were scheduled from March to December 2015 and included aortic imaging as well as peripheral blood sampling for genetic testing. Next-generation sequencing libraries were prepared using a custom-made HaloPlex HS gene panel and included 20 candidate genes known to be associated with aortopathy and BAV. The primary end-point was the prevalence of genetic defects in our study cohort. RESULTS: A total of 63 patients (mean age 46 ± 10 years, 92% men) with BAV root phenotype and mean post-aortic valve replacement follow-up of 10.3 ± 4.9 years were included. Our genetic analysis yielded a wide spectrum of rare, potentially or likely pathogenic variants in 19 (30%) patients, with NOTCH1 variants being the most common ( n = 6). Moreover, deleterious variants were revealed in AXIN1 ( n = 3), NOS3 ( n = 3), ELN ( n = 2), FBN1 ( n = 2) , FN1 ( n = 2) and rarely in other candidate genes. CONCLUSIONS: Our preliminary study demonstrates a high prevalence and a wide spectrum of rare genetic variants in patients with the BAV root phenotype, indicative of the potentially congenital origin of associated aortopathy in this specific BAV cohort.
Asunto(s)
Válvula Aórtica/anomalías , ADN/genética , Predicción , Biblioteca de Genes , Enfermedades de las Válvulas Cardíacas/genética , Polimorfismo Genético , Adolescente , Adulto , Anciano , Válvula Aórtica/cirugía , Enfermedad de la Válvula Aórtica Bicúspide , Estudios Transversales , Ecocardiografía , Femenino , Estudios de Seguimiento , Pruebas Genéticas , Enfermedades de las Válvulas Cardíacas/diagnóstico , Enfermedades de las Válvulas Cardíacas/cirugía , Implantación de Prótesis de Válvulas Cardíacas , Humanos , Imagen por Resonancia Cinemagnética , Masculino , Persona de Mediana Edad , Fenotipo , Estudios Retrospectivos , Adulto JovenRESUMEN
Antagonists of growth hormone releasing hormone (GHRH) directly inhibit the growth of a variety of human neoplasms. However, the plasma membrane receptor mediating these effects has not been immunocytochemically visualised in primary tumour cells. Given that previous attempts using an antibody to the amino-terminal region did not result in the visualisation of plasma membrane receptors, we have developed and characterised an anti-peptide antibody to the carboxy-terminal region 403-422 of the human pituitary GHRH receptor. This sequence is identical to residues 339-358 of splice variant 1 (SV1) of tumoural GHRH receptors. Specificity of the antibody was demonstrated by (1) immunocytochemical staining of GHRH receptor-transfected cells, (2) detection of a broad glycosylated protein band migrating at Mr 50,000-60,000 in Western blots of membranes from human pituitary, and (3) abolition of tissue immunostaining by preadsorbtion of the antibody with its immunising peptide. The distribution of GHRH receptors was investigated in 69 formalin-fixed, paraffin-embedded human tumours showing that GHRH receptors were frequently expressed in breast, ovarian and prostate carcinomas. Immunoreactive GHRH receptors were clearly confined to the plasma membrane and uniformly present on nearly all tumour cells. In Western blots of membranes prepared from human tumours, the anti-GHRH receptor antibody detected a non-glycosylated protein band migrating at Mr 40,000, which corresponds to the expected molecular weight of splice variant 1 of tumoural GHRH receptors. Together, our findings provide direct evidence for the presence of GHRH receptor protein on the plasma membrane of primary human tumour cells. The GHRH receptor visualisation could be of value for a rapid immunohistochemical identification of those tumours which could be a target for diagnostic or therapeutic intervention using GHRH analogues.
Asunto(s)
Anticuerpos/análisis , Membrana Celular/metabolismo , Proteínas de Neoplasias/metabolismo , Neoplasias/diagnóstico , Péptidos/inmunología , Receptores de Neuropéptido/metabolismo , Receptores de Hormona Reguladora de Hormona Hipofisaria/metabolismo , Humanos , Inmunohistoquímica/métodos , Proteínas de Neoplasias/inmunología , Receptores de Neuropéptido/inmunología , Receptores de Hormona Reguladora de Hormona Hipofisaria/inmunologíaRESUMEN
Biological effects of substance P (SP) are mediated by the neurokinin-1 (NK1) receptor that exists as a full-length and as a carboxy-terminally truncated isoform in humans. Although NK1 receptor mRNA and binding sites have been detected in certain malignancies, little is known about the cellular and subcellular localization of NK1 receptor protein in human neoplastic tissues. We developed and characterized a novel anti-peptide antibody to the carboxy-terminal region of the human full-length NK1 receptor. Specificity of the antiserum was demonstrated by (1) detection of a broad band migrating at molecular mass 70,000-90,000 Da in Western blots of membranes from NK1-expressing tissues; (2) cell-surface staining of NK1-transfected cells; (3) translocation of NK1 receptor immunostaining after SP exposure; and (4) abolition of tissue immunostaining by preadsorption of the antibody with its immunizing peptide. Distribution of NK1 receptors was investigated in 72 formalin-fixed, paraffin-embedded human tumors showing that NK1 receptors were frequently expressed in glioblastomas and breast and pancreatic carcinomas. Immunoreactive NK1 receptors were clearly confined to the plasma membrane and uniformly present on nearly all tumor cells. Development of this novel NK1 receptor antibody allows the efficient localization of NK1 receptor protein in human formalin-fixed, paraffin-embedded tissues. NK1 receptor visualization with this simple and rapid immunohistochemical method will facilitate identification of tumors with a sufficient receptor overexpression for diagnostic or therapeutic intervention using SP analogs.
Asunto(s)
Neoplasias/metabolismo , Receptores de Neuroquinina-1/metabolismo , Anticuerpos , Especificidad de Anticuerpos , Línea Celular , Fijadores , Formaldehído , Humanos , Inmunohistoquímica , Adhesión en Parafina , Fragmentos de Péptidos/inmunología , Receptores de Neuroquinina-1/inmunologíaRESUMEN
The biological effects of neurotensin (NT) are mediated by two distinct G protein-coupled receptors, NTS(1) and NTS(2). Although it is well established that neurotensin inhibits gastric acid secretion in man, the plasma membrane receptor mediating these effects has not been visualized yet. We developed and characterized a novel antipeptide antibody to the carboxy-terminal region of the human NTS(2) receptor. The cellular and subcellular distribution of NTS(2) receptors was evaluated in various human gastrointestinal tissues. Specificity of the antiserum was demonstrated by (1) detection of a broadband migrating at M(r) 90 000-100 000 in Western blots of membranes from NTS(2)-expressing tissues; (2) cell-surface staining of NTS(2)-transfected cells; (3) translocation of NTS(2) receptor immunostaining after agonist exposure; and (4) abolition of tissue immunostaining by preadsorbtion of the antibody with its immunizing peptide. In the gastrointestinal tract, NTS(2) receptor immunoreactivity was highly abundant in parietal cells of the gastric mucosa, in neuroendocrine cells of the stomach small and large intestine, and in cells of the exocrine pancreas. NTS(2) receptors were clearly located in the plasma membrane and uniformly present on nearly all target cells. The presence of NTS(2) receptors was rarely detected in human tumors. This is the first localization of NTS(2) receptors in human formalin-fixed, paraffin-embedded tissues at the cellular level. The abundant expression of low-affinity NTS(2) receptors on the plasma membrane of human parietal cells provides a morphological substrate for the direct inhibition of gastric acid secretion observed after i.v. administration of neurotensin.
Asunto(s)
Membrana Celular/química , Células Parietales Gástricas/química , Receptores de Neurotensina/análisis , Anticuerpos Monoclonales/aislamiento & purificación , Anticuerpos Monoclonales/farmacología , Western Blotting/métodos , Humanos , Inmunohistoquímica/métodos , Insulinoma/química , Intestinos/química , Masculino , Neurotensina/metabolismo , Análisis de Secuencia por Matrices de Oligonucleótidos , Adhesión en Parafina , Unión Proteica , Receptores de Neurotensina/genética , Neoplasias Gástricas/químicaRESUMEN
Bombesin (BN)-like peptides can stimulate cancer cell growth through binding to their specific G protein-coupled receptors. It is well established that BN receptors are being overexpressed in a subset of human tumors; however, little is known about the cellular and subcellular localization of individual BN receptor subtypes in these tissues. In this study, we developed and characterized novel antipeptide antibodies to the carboxy terminal regions of the gastrin-releasing peptide-preferring bombesin receptor (GRP-R) and the bombesin receptor subtype-3 (BRS-3). Specificity of the antisera was demonstrated by (1) detection of broad bands migrating at Mr 50,000-70,000 in Western blots of membranes from receptor-expressing tissues; (2) cell surface staining of transfected cells; (3) translocation of GRP-R receptor immunostaining after BN exposure; and (4) abolition of tissue immunostaining by preadsorbtion of the antibodies with their immunizing peptides. The distribution of BN receptors was investigated in 74 formalin-fixed, paraffin-embedded human tumors. GRP-R receptors were most frequently detected in breast and prostate carcinomas. BRS-3 receptors were often detected in prostate and pancreatic carcinomas and in pituitary adenomas. Immunoreactive GRP-R and BRS-3 receptors were in many cases predominantly confined to the plasma membrane and uniformly present on nearly all tumor cells. The development of these novel antipeptide antibodies will facilitate the identification of those tumors, which may be targets for diagnostic or radiotherapeutic application of subtype-selective BN analogs.
Asunto(s)
Anticuerpos Antineoplásicos/biosíntesis , Técnicas para Inmunoenzimas/métodos , Receptores de Bombesina/análisis , Secuencia de Aminoácidos , Animales , Anticuerpos Antineoplásicos/inmunología , Biomarcadores de Tumor/análisis , Biomarcadores de Tumor/química , Biomarcadores de Tumor/inmunología , Femenino , Técnica del Anticuerpo Fluorescente Directa , Humanos , Masculino , Datos de Secuencia Molecular , Neoplasias , Péptidos/química , Péptidos/inmunología , Conejos , Receptores de Bombesina/química , Receptores de Bombesina/inmunologíaRESUMEN
BACKGROUND: The biological effects of cholecystokinin (CCK) are mediated by two distinct G protein-coupled receptors, CCK1 and CCK2. Although it is well established that CCK receptors are widely distributed throughout the normal gastrointestinal tract, little is known about their cellular and subcellular localization in human normal and neoplastic tissues. METHODS: We developed and characterized a novel antipeptide antibody to the carboxyl-terminal region of the human CCK1 receptor. Specificity of the antiserum was demonstrated by 1) detection of a broad band migrating at a relative molecular mass of 85,000-95,000 in Western blots of membranes from CCK1-expressing tumors and CCK1-transfected cells, 2) cell surface staining of CCK1-transfected cells, 3) translocation of CCK1 receptor immunostaining after agonist exposure, and 4) abolition of tissue immunostaining by preadsorption of the antibody with its immunizing peptide. The distribution of CCK1 receptors was investigated in 74 human tumors and their tissues of origin. RESULTS: The presence of CCK1 receptors was rarely detected in human tumors except for carcinoids, insulinomas, pituitary adenomas, and meningiomas. CCK1 receptors were clearly located at the plasma membrane and uniformly present on nearly all tumor cells. In the gastrointestinal tract, CCK1 receptor immunoreactivity was highly abundant in chief cells of the gastric mucosa, in myenteric ganglion cells, and in myenteric nerve fibers. CONCLUSION: This is the first localization of CCK1 receptors in human formalin-fixed, paraffin-embedded tissues at the cellular level. The overexpression of CCK1 receptors in a subset of human neuroendocrine tumors may provide a molecular basis for efficient targeting of these tumors with radiolabeled CCK analogs.